Buy Topamax through the unique service that maximize your savings

Clinical Psychiatry News - Treating olanzapine-linked adiposity.(CLINICAL CAPSULES)(Brief Article)

admin — Sun, 16 Nov 2008 11:26:03 +0000

Jun 15, 2005 (The Sydney Morning Herald - ABIX via COMTEX)

Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
IBM and SAP: Innovate. Collaborate. Grow.

Drug companies have refused to lower the price of four drugs in Australia, despite pressure from the Federal Government. The drugs are Alimta, for lung cancer, Topamax, for epilepsy, Keppra, for migraine, and Lexapro, for depression. From 1 August 2005, patients using these drugs will pay more, on top of what they already pay. The Australian Government is doing all it can to lower the price it pays drug companies. The Government wants to see greater use made of generic medicines, which are …

Read the rest of this article with a Free Trial at HighBeam Research.

Pharmacy News - $130m new PBS listings.(new products marketing for the chronic kidney disease, psoriasis and migraine patinets in Australia)(Brief article)

admin — Fri, 14 Nov 2008 06:21:04 +0000

Simone Roberts
Health minister Tony Abbott has announced $130 million in PBS listings while campaigning during the last month.
PATIENTS suffering from chronic kidney disease, psoriasis and migraine will benefit from the new listings.
Subsidised access through the PBS will become available for Renagel (sevelamer), Remicade (infliximab) and Topamax (topiramate).

Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speakingn 13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers

About 3200 people will commence Renagel for the management of chronic kidney disease in the first full financial year of listing at an extra cost of around $65 million to PBS and Repatriation Pharmaceutical Benefits …

Read the rest of this article with a Free Trial at HighBeam Research.

Chain Drug Review - Judgefinds for J&J.(Digest)(Johnson & Johnson wins case)(Brief article)

admin — Fri, 07 Nov 2008 18:25:04 +0000

A federal judge in New Jersey ruled in favor of Johnson & Johnson in a dispute over the patent for Topamax, its epilepsy …

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

Read the rest of this article with a Free Trial at HighBeam Research.

Saturday Evening Post - Migraine in the news

admin — Sat, 01 Nov 2008 14:10:55 +0000

A novel treatment for recurrent migraines combines the antiwrinkle drug Botox and surgery. Dr. Jeffrey Janis, a plastic surgeon at UT Southwestern Medical Center at Dallas who helped pioneer the procedure, explains that Botox injections can help identify muscles in the head that may be irritating nerves and causing migraines.

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

If the Botox therapy eases migraines, surgery to remove the targeted muscle may provide a more long-term solution in some cases. Another UT Southwestern research group reports that the drug topiramate (Topamax), commonly used to treat migraines and seizures, may increase the risk of calcium phosphate kidney stones.
COPYRIGHT 2007 Saturday Evening Post Society
COPYRIGHT 2007 Gale Group

Internal Medicine News - Topamax.(Brief Article)

admin — Thu, 30 Oct 2008 01:36:17 +0000

(toipiramate, Ortho-McNeil Pharmaceutical Inc.)

An anticonvulsant for add-on therapy in people aged 2 and older with seizures related to Lennox-Gastaut syndrome. Previously approved as adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures.

* Dosage: 400 mg a day in two divided doses (for age 17 and over).

Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid

* Special Considerations: Sleepiness, poor coordination, speech difficulties, psychomotor slowing, blurred or double vision, and memory difficulties may occur but are generally temporary according to the manufacturer. Acute myopia …

Read the rest of this article with a Free Trial at HighBeam Research.

AsiaInfo Services - JOHNSON & JOHNSON TO CUT 4,800 JOBS GLOBALLY

admin — Mon, 27 Oct 2008 14:16:37 +0000

Most Popular
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
Request For Interview

>
AsiaInfo Services

03-12-2008

Johnson & Johnson to Cut 4,800 Jobs Globally

BEIJING, Aug 03, 2008 (SinoCast via COMTEX) — The US-based Johnson & Johnson, a world’s top producer of medical and health care products, announced in the recent days that it would cut 3% to 4% of its global jobs, up to 4,800 persons, while its Chinese branch indicated that the move would not impact the Chinese market.

It is mainly because the patent valid period of Risperdal and Topamax, the company’s two best-selling medicine brands, will expire in 2008.

Currently, the US company, having …

Read the rest of this article with a Free Trial at HighBeam Research.

Business Wire - Zacks.com Announces That Vivian Lewis Highlights the Following Stocks: Teva, ICICI Bank Ltd and Sanofi

admin — Sun, 26 Oct 2008 07:56:48 +0000

BRECKENRIDGE, COLO. — Topiramate monotherapy at a target dosage of 100 mg/day–substantially less than conventional dosing–is at least as effective as standard therapeutic doses of carbamazepine or valproate for newly diagnosed epilepsy regardless of seizure type, Jacci Bainbridge, Pharm.D., said at a conference on epilepsy syndromes sponsored by the University of Texas at San Antonio.

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

Moreover, for this purpose topiramate (Topamax) at 100 mg/day has markedly fewer side effects and costs less than the much more widely used 200 mg/day dosing–and with no significant drop-off in …

Read the rest of this article with a Free Trial at HighBeam Research.

PR Newswire Europe - New Long-Term Clinical Studies and Health-Related Quality of Life Data Show Promise of Topamax(R) in Prevention of Migraine Episodes.

admin — Tue, 21 Oct 2008 11:42:28 +0000

ATHENS, Greece, September 19 /PRNewswire/ — Results from two large clinical trials demonstrate that patients with frequent migraine who were treated with TOPAMAX(R) (topiramate) for up to 14 months (6 months double blind followed by 8 months open label) had a persistent reduction in the frequency of migraine headaches(1).

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

In addition, analyses from the three 26-week placebo-controlled pivotal trials of topiramate in migraine prevention showed that topiramate improves health-related quality of life (HRQoL)(2). These data were presented today at the ninth congress of the European …

Read the rest of this article with a Free Trial at HighBeam Research.

Medical Marketing and Media - Best Media Planning/Buying Campaign in Professional Media

admin — Sun, 19 Oct 2008 18:32:44 +0000

Sponsored by Corbett Accel Healthcare Group
GOLD AWARD
Conetics and Ortho-McNeil Neurologies for Topamax Migraine
2007 Media Plan for Topamax Migraine
Judges awarded the Gold for Ortho-McNeil Neurologies’ Topmax campaign’s segmentation strategy, calling it a “nicely executed, well thought-out segmentation analysis.”
Topamax is a widely prescribed migraine preventative, boasting strong sales which are attributable to the migraine indication as well as to its use for epilepsy.
The media plan emphasizes the audiences of primary care physicians, physician assistants, and nurse practitioners. The marketing budget was allocated across all media channels, including print and e-media.

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

Judges were particularly impressed with the new HCP Web portal and its online resource topamax360.com, which offers Medical Economics podcasts and Web seminars presented by key opinion leaders on a broad range of medical hot topics including practice management, professional development, online CME, personnel and ethics issues, and real-time breaking news in the field of neurology.
The Web site also offers an electronic version of the MPR Neurologists Edition, as well as the eMPR Concise Drug Database.
Print media such as journals and prescription pads are consistently linked to the HCP portal. The campaign focused on publications that deliver practice management and news editorial that can be linked to offerings like those found on Topamax360.com.
Doctor’s Digest provides practical, how-to solutions from thought leaders and experts aimed to make physicians’ clinical practice and professional career more successful and satisfying.
The TOPAMAX CAN Program puts patients in touch with knowledgeable healthcare professionals to get answers to their questions about TOPAMAX via a toll-free number: Additionally, integrated media programs drove traffic to Topamax360.com and promoted interactivity at the portal.
Our judges gave the entry unanimously high marks and called it a “very successful, creative program” that “uses segmentation effectively.”
SILVER AWARD
Communications Media and GlaxoSmffliKline and Astrellas for Vesicare
Vesicare 2006 Professional Media Plan
Vesicare entered the highly competitive OAB market as a late entry product, yet still made a strong impact and held a strong market share against its competitors in its first year on the market. The campaign targeted primary care physicians, urologists, and Ob/Gyns with the objective of creating awareness of the Vesicare core message and producing loyalty among its key targets. Judges praised the campaign as “thorough” and “innovative,” and as a “professional example of successful media planning.”
The Award
Recognizes excellence from media agencies and in-house planning and buying departments whose work harnesses the power of media in the service of advertisers in professional media.
The Finalists
* AbelsonTaylor and Astellas Pharma for Amevive-Amevive 2007 Campaign
* Communications Media and GlaxoSmithKline and Astellas for Vesicare-Vesicare 2006 Professional Media Plan
* Conetics and Ortho-McNeil Neurologies for Topamax Migraine-2007Media Plan for Topamax Migraine
Corbett Accel Healthcare Group is one of the largest healthcare communications companies in the world and a part of Omnicom Group Inc. Corbett Accel business units include Corbett Worldwide Healthcare Communications; Surge Worldwide Healthcare Communications; Iris Global Clinical Trial Solutions; Kinect (full service interactive); and Accel Health (promotional medical education).
Copyright Haymarket Media, Inc. 2007
Provided by ProQuest Information and Learning Company. All rights Reserved

PR Newswire - FDA Grants Pediatric Exclusivity for TOPAMAX®, Extending the Marketing Exclusivity by Six Months

admin — Thu, 16 Oct 2008 15:38:09 +0000

TITUSVILLE, N.J., July 24 /PRNewswire/ — Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for TOPAMAX(R) (topiramate), based on studies submitted in response to a Written Request by the FDA to investigate the use of TOPAMAX in pediatric patients aged 1 to 24 months with partial onset seizures.
In addition to granting pediatric exclusivity, the FDA is continuing its review of the application to determine the safety and efficacy of TOPAMAX in this patient population. Based on the data submitted, no indication is sought for this age group.

Related Results

Ortho-McNeil, J&J step up the fight against dispensing errors.(OrthoMcNei…

NEWS: Update

WALL STREET CHOICE J&J SHARES REFLECT SLOWING PHARMA GROWTH

Safety Alert Issued for Topiramate

New indication for antiepieptic drug

A recent court decision confirmed the validity of the TOPAMAX patent, which is set to expire in September 2008. However, this grant will extend the period of exclusivity through March 2009. TOPAMAX is not approved for use in pediatric patients aged 1 to 24 months.
TOPAMAX(R) is indicated as initial monotherapy in patients 10 years of age and older with partial onset seizures or generalized tonic-clonic seizures. It also is indicated as adjunctive therapy for adults and children (aged two and above) with partial onset seizures or generalized tonic-clonic seizures, and in adults and children as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome. TOPAMAX(R) is indicated in adults for the prophylaxis of migraine headache.
Important Safety Information: Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an increase in the acidity of the blood (metabolic acidosis). Symptoms could include hyperventilation (rapid, deep breathing), tiredness, loss of appetite, irregular heartbeat or changes in the level of alertness. Call your doctor immediately if you get these symptoms. Your doctor may want to do simple blood tests. Chronic, untreated metabolic acidosis may increase the risk for kidney stones or bone disease.
Other serious risks include decreased sweating, increased body temperature, kidney stones, sleepiness, dizziness, confusion, difficulty concentrating, and increased eye pressure (glaucoma). Call your doctor immediately if you have any decrease in vision or eye pain. These problems can lead to blindness if not treated right away.
More common side effects are tingling in arms and legs, loss of appetite, tiredness, nausea, diarrhea, taste change and weight loss.
Headquartered in Titusville, NJ, Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., focuses exclusively on providing solutions that improve neurological health. The company currently markets products for Alzheimer’s disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to explore new opportunities to develop solutions for unmet health care needs in neurology.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a wholly-owned subsidiary of Johnson & Johnson, the world’s most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com/.
(This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov/, http://www.jnj.com/ or on request from Johnson & Johnson. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
CONTACT: Media, Kara Russell, 1-609-730-3592, Krussel3@prdus.jnj.com, or Investors, Louise Mehrotra, 1-732-524-6491, or Lesley Fishman, 1-732-524-3922, all of Johnson & Johnson for Ortho-McNeil-Janssen Pharmaceuticals, Inc.